On Sunday morning, Dr. Fiona Crawford, Associate Director and Vice President of the Roskamp Institute, was one of four presenters participating in a press conference titled," 'Invisible' Wounds: From Soldiers to Citizens", which focused on traumatic brain injury research working to improve the lives of citizens and soldiers. In the press conference, Dr. Crawford described the Roskamp Institute's larger traumatic brain injury research program and the Institute's work investigating anatabine's effect in laboratory models of TBI.
On Monday morning, Dr. Scott Ferguson, also of the Roskamp Institute, presented these data in a presentation titled, "TBI-Induced Spatial Memory Loss is Averted by Treatment with the Dietary Supplement Anatabine". In this study, three groups of mice were studied: One group of TBI mice was treated with anatabine, while a second group of TBI mice was untreated. A third group was comprised of normal mice. The results of the study showed that the untreated TBI mice demonstrated memory impairment; whereas, the memory of anatabine treated TBI mice was the same as normal mice. The scientists at the Roskamp Institute hypothesize that the maintenance of normal memory in TBI mice treated with anatabine is due to an inhibition of inflammation. The presentation abstract notes: "Anatabine treatment appeared to completely prevent the loss of spatial memory retention following severe TBI."
Dr. Crawford stated, "Further study of this promising treatment is warranted and will include evaluation in a mild closed head injury model as well as assessment of long term outcome from injury." Dr. Michael Mullan, President and CEO of the Roskamp Institute, explained, "Dietary supplementation to prevent memory loss after head injury has a potentially rapid development path for human use." According to the Centers for Disease Control, 1.7 million people in the United States experience TBI each year, with 80,000 survivors suffering long-term disability.
In addition to the TBI research, the Roskamp Institute presented results of its research examining the potential benefit of anatabine for alleviating symptoms associated with Multiple Sclerosis and will present new research on anatabine's effect on Alzheimer's Disease at the conference. For more information about the TBI study and the MS study, visit the Roskamp Institute's website at: http://www.rfdn.org
http://www.prnewswire.com/news-releases ... 18821.html
GLEN ALLEN, Va., Oct. 16, 2012 /PRNewswire/ -- Star Scientific, Inc. (STSI) through its wholly owned subsidiary, Rock Creek Pharmaceuticals Inc., reports that earlier in the week scientists from its research partner, the Roskamp Institute, presented results of its recent research showing that anatabine supplementation significantly reduces central and peripheral inflammation and neurological injury in an animal model of multiple sclerosis (MS). The findings were presented in New Orleans, Louisiana, at Neuroscience 2012, the 42nd annual meeting of the Society for Neuroscience, as part of a series of presentations by researchers from the Roskamp Institute on supplementation with anatabine, the active ingredient in the Company's Anatabloc® dietary supplement. Neuroscience 2012 is the world's largest and most prestigious scientific meeting dedicated to brain and neurological science. Preliminary results were reported previously on the Roskamp Institute's website; however, this recent presentation contained new and expanded findings and marked the first time these data have been presented at an international scientific convention.The presentation titled, "Amelioration of Experimental Autoimmune Encephalomyelitis by Anatabine Through Inhibition of Stat3 and NFkappaB Signaling Pathways" showed how researchers at the Roskamp Institute assessed the effects of anatabine supplementation in mice with EAE (experimental autoimmune encephalomyelitis). This condition is induced in the mice by vaccinating them with myelin, which causes an autoimmune reaction. As a consequence, there is a severe inflammatory process in the brain that causes progressive paralysis similar to that which occurs in human MS. Dietary supplementation with anatabine had a significant positive effect in reducing neurological disability and improving motor coordination of EAE mice. Results showed that 86% (13 of 15) of the mice that received anatabine supplementation had no significant hindlimb paralysis after treatment, with only 2 mice experiencing complete posterior hindlimb paralysis. In contrast, only 33% (5 of 15) of placebo-treated mice had no significant hindlimb paralysis.
In addition to the beneficial effects on motor performance, anatabine supplementation resulted in suppression of pro-inflammatory molecules induced by EAE in the spleen and serum such as IFN-gamma, IL-1 beta, IL-6, IL-17, and TNF-alpha and greatly suppressed elevated levels of IFN-gamma and TNF-alpha in the brain of EAE mice.
The Roskamp Institute also presented research at Neuroscience 2012 on the role of anatabine supplementation in facilitating recovery from traumatic brain injury (TBI). Dr. Michael Mullan, President and CEO of the Roskamp Institute, noted: "Both TBI and Multiple Sclerosis have in common massive brain inflammation. The reason anatabine supplementation looks so promising in both of these conditions is likely because, as we have previously shown, it is a potent anti-inflammatory agent. Although anatabine's anti-inflammatory activity may have different roles in each of these conditions the net result is to reduce the clinical and neuropathological consequences."
For more information about the MS research, as well as the TBI research, please visit the Roskamp Institute's website at: http://www.rfdn.org.
http://finance.yahoo.com/news/beneficia ... 00604.html
I could only found this on it in Pub Med.
Endocrinology. 2012 Sep;153(9):4580-7. doi: 10.1210/en.2012-1452. Epub 2012 Jul 17.
Anatabine ameliorates experimental autoimmune thyroiditis.
Caturegli P, De Remigis A, Ferlito M, Landek-Salgado MA, Iwama S, Tzou SC, Ladenson PW.
Department of Pathology, Johns Hopkins University School of Medicine, Ross 656, 720 Rutland Avenue, Baltimore, Maryland 21205, USA. email@example.com
Tobacco smoking favorably influences the course of Hashimoto thyroiditis, possibly through the antiinflammatory proprieties of nicotine. In this study we tested anatabine, another tobacco alkaloid, in a model of experimental autoimmune thyroiditis. Experimental autoimmune thyroiditis was induced by different doses of thyroglobulin, to produce a disease of low, moderate, or high severity, in 88 CBA/J female mice: 43 drank anatabine supplemented water and 45 regular water. Mice were bled after immunization and killed to assess thyroid histopathology, thyroglobulin antibodies, T(4), and thyroid RNA expression of 84 inflammatory genes. We also stimulated in vitro a macrophage cell line with interferon-γ or lipopolysaccharide plus or minus anatabine to quantitate inducible nitric oxide synthase and cyclooxygenase 2 protein expression. Anatabine reduced the incidence and severity of thyroiditis in the moderate disease category: only 13 of 21 mice (62%) developed thyroid infiltrates when drinking anatabine as compared with 22 of 23 (96%) controls (relative risk 0.59, P = 0.0174). The median thyroiditis severity was 0.5 and 2.0 in anatabine and controls, respectively (P = 0.0007 by Wilcoxon rank sum test). Anatabine also reduced the antibody response to thyroglobulin on d 14 (P = 0.029) and d 21 (P = 0.045) after immunization and improved the recovery of thyroid function on d 21 (P = 0.049). In the thyroid transcriptome, anatabine restored expression of IL-18 and IL-1 receptor type 2 to preimmunization levels. Finally, anatabine suppressed in a dose-dependent manner macrophage production of inducible nitric oxide synthase and cyclooxygenase 2. Anatabine ameliorates disease in a model of autoimmune thyroiditis, making the delineation of its mechanisms of action and potential clinical utility worthwhile.
PMID: 22807490 [PubMed - indexed for MEDLINE]